Bionavigen is a biopharmaceutical navigation company that specializes in providing consulting services for the entire drug development process, from discovery to regulatory sciences. Their expertise lies in smart acquisition, allowing them to navigate the complex landscape of new drug development with confidence. Bionavigen offers a range of services, including drug hunting, ADC (Antibody Drug Conjugate) development, immuno-oncology, preclinical and clinical development, CMC (Chemistry, Manufacturing, and Controls) translation sciences, and regulatory sciences.

They have a team of virtual full drug developers who are actively engaged in acquiring clinical stage biologics and small molecule drugs from pharmaceutical companies, supported by funds from VC investment firms. With over 30 years of experience, Bionavigen has successfully marketed over 10 biopharmaceuticals, with more than 100 INDs and 15 BLAs-NDAs under their belt. They prioritize promising drug candidates in new disease indications or through innovative combinations, backed by investor funding.

For comprehensive, real-world drug development experience-based consulting services, Bionavigen is the trusted choice